Skip to content
AnalystLens

Idex Annual Report, Year Ended Dec 31, 2002

Filing Date
Filed February 28, 2003
Period End
December 31, 2002
Security
IEX
In the record · 2016–202610-K1110-Q338-K119

IEX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. FY2016 annual report10-K · Feb ’17Feb ’17
  2. Material agreement8-K · Jun ’19Jun ’19
  3. Leadership change8-K · Feb ’22Feb ’22
  4. Leadership change8-K · Dec ’25Dec ’25

Summary

Summary of the 10-K filed February 28, 2003. Cited figures are marked; the original filing is the authoritative source.

IDEX Corporation (NYSE and Chicago Stock Exchange: IEX) reported 2002 net sales of $742.0 milliona, up from $726.9 million in 2001, and net income of $54.1 million, or $1.67 per diluted share, versus $32.7 million, or $1.05 per share, in 2001.

Operating income rose to $100.4 millionb from $73.4 million, helped by the absence of goodwill and trademark amortization in 2002 (which had been $14.6 million in 2001) and the lack of a 2001 restructuring charge of $11.2 million. Operating margin was 13.5% compared with 10.1% in 2001. New orders totaled $749.8 million, 5% higher than 2001, but excluding acquisitions and currency, orders were only 1% higher, and management stated it saw no significant market recovery during 2002 and no indication that sluggishness in end markets would change soon.

The company operates three segments: Pump Products Group (58% of 2002 sales, 62% of operating income), Dispensing Equipment Group (19% of sales, 16% of operating income), and Other Engineered Products Group (23% of sales, 22% of operating income). Cash flow from operations was $108.4 millionc and free cash flow was $89.1 million. Total debt fell to $241.1 million from $291.8 million, and shareholders' equity rose to $506.8 million from $401.1 million, reflected in a $50.8 million common stock offering in 2002.

Management said the company is well positioned for earnings improvement as the economy strengthens, and that it continues to pursue acquisitions such as Rheodyne, Halox and Wrightech, which were acquired in 2002 for $74.9 milliond. The company is named as a defendant in asbestos-related personal injury lawsuits along with five subsidiaries.

Components were sourced from third-party suppliers, and settlements and legal costs have been largely covered by insurance, though the company cannot predict future insurance availability. No provision has been made in the financial statements, and management does not currently believe these claims will have a material adverse effect.

Key Highlights

  1. 2002 net sales of $742.0 million, 2% above 2001's $726.9 million; net income of $54.1 million, or $1.67 per diluted share, versus $1.05 in 2001
  2. Operating income rose 37% to $100.4 million, with operating margin of 13.5% versus 10.1% in 2001, aided by no goodwill amortization in 2002 and no 2001-style restructuring charge
  3. New orders of $749.8 million were 5% higher than 2001, but only 1% higher excluding acquisitions and foreign currency translation
  4. Free cash flow of $89.1 million in 2002, with operating cash flow of $108.4 million
  5. Total debt reduced to $241.1 million from $291.8 million; shareholders' equity increased to $506.8 million, including a $50.8 million common stock offering
  6. Pump Products Group contributed 58% of 2002 sales and 62% of operating income; international sales were 41% of total sales
  7. Asbestos-related lawsuits name IDEX and five subsidiaries; management does not currently believe they will have a material adverse effect, though insurance coverage for future claims is uncertain

Frequently Asked Questions

  1. How did IDEX's profitability change in 2002?

    Net income rose to $54.1 million, or $1.67 per diluted share, from $32.7 million, or $1.05 per share, in 2001. The improvement was primarily due to the absence of goodwill and trademark amortization in 2002, which had been $14.6 million in 2001, the absence of the $11.2 million restructuring charge recorded in 2001, and higher gross profit, partly offset by increased SG&A expenses.

  2. Is demand recovering in IDEX's end markets?

    Management stated that 2002 was a very difficult year, with no significant recovery in its markets. New orders were 5% higher than 2001, but excluding acquisitions and foreign currency translation, orders were only 1% higher. Management said there is no indication that sluggishness in U.S. and worldwide end markets will change soon and is not in a position to project how the economy will perform over the next year.

  3. How strong is IDEX's balance sheet and cash generation?

    Operating cash flow was $108.4 million in 2002, and free cash flow was $89.1 million. Total debt declined to $241.1 million from $291.8 million, and the current ratio was 2.0-to-1 at year-end. Management said the company will generate sufficient cash flow to meet its operating requirements, interest, planned capital expenditures and dividends over the next 12 months and in the long term.

  4. What are the main risks from asbestos-related claims?

    IDEX and five of its subsidiaries are defendants in asbestos-related personal injury lawsuits, which allege exposure to products containing components purchased from third-party suppliers. Settlements and legal costs, except for certain coordination, administration, insurance investigation and a portion of defense costs, have been covered by insurance. The company cannot predict whether insurance will continue to cover such costs, and no provision has been made in the financial statements.

  5. What is IDEX's business mix and growth strategy?

    IDEX has three segments: Pump Products (58% of 2002 sales), Dispensing Equipment (19%) and Other Engineered Products (23%). The company says each principal business unit holds the number-one or number-two market share in its niche and pursues strategic acquisitions. In 2002 it acquired Halox, Rheodyne and Wrightech for $74.9 million, and management says it continues to pursue acquisitions to drive longer-term profitable growth.